Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
The study included 19 patients with Stage II-IV (12 of whom had Stage II/IIIa) breast cancer who have undergone ablative chemotherapy to treat their cancer. Aastrom and Loyola said patients received transplants of stem cells produced from a small volume of autologous bone marrow in the AastromReplicell System using the SC-1 Therapy Kit. The study was intended to evaluate whether stem cells produced ex vivo could be used by themselves to restore blood and immune system function following aggressive chemotherapy and evaluated the time to engraftment of the patients' key infection fighting white blood cells and blood-clotting cells to control bleeding.
Aastrom has developed two therapy kits, the SC-1 Therapy Kit for the production of bone marrow-derived stem cells and the CB-1 Kit for the production of cord blood cells. The company has initiated a Phase III-pivotal clinical trial evaluating the SC-1 Therapy Kit in breast cancer patients and plans to initiate a Phase III-pivotal trial of the CB-1 Therapy Kit.
Contact: Todd Simpson - (734) 930-5777
|Printer friendly Cite/link Email Feedback|
|Comment:||Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.|
|Article Type:||Brief Article|
|Date:||Mar 27, 2000|
|Previous Article:||Paraplegic takes first steps in 10 years after implanted micro chip restores nerve function.|
|Next Article:||ABIOMED forms collaborative agreement with Rabin Medical Center to test AbioCor implantable replacement heart.|